Estrella Immunopharma Inc. (ESLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has a cash flow conversion efficiency ratio of 0.240x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.78 Million) by net assets ($-7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Estrella Immunopharma Inc. stock valuation for the company's overall valuation and market capitalisation.
Estrella Immunopharma Inc. - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Estrella Immunopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Estrella Immunopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Estrella Immunopharma Inc. ranked by their cash flow conversion efficiency. See how well can Estrella Immunopharma Inc. service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wemade Max Co. Ltd
KQ:101730
|
-0.016x |
|
TOP Ships Inc.
NASDAQ:TOPS
|
0.110x |
|
Sierra Nevada Gold Inc
AU:SNX
|
-0.044x |
|
Happy Creek Minerals Ltd
V:HPY
|
-0.016x |
|
Audacia SAS
PA:ALAUD
|
-0.098x |
|
PT Wahana Interfood Nusantara Tbk
JK:COCO
|
-0.003x |
|
Tigers Realm Coal Ltd
AU:TIG
|
-0.316x |
|
Pato Chemical Industry Public Company Limited
BK:PATO
|
0.101x |
Annual Cash Flow Conversion Efficiency for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2025. View ESLA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.37 Million | $-1.79 Million | 0.172x | +100.80% |
| 2024-12-31 | $143.73K | $-3.11 Million | -21.662x | -476.12% |
| 2023-12-31 | $4.27 Million | $-16.07 Million | -3.760x | -2446.93% |
| 2022-12-31 | $7.07 Million | $-1.04 Million | -0.148x | -110.65% |
| 2021-12-31 | $-1.04 Million | $-1.44 Million | 1.387x | -- |
| 2020-12-31 | $0.00 | $-670.82K | x | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more